Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "clinical-data"

241 News Found

Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer
Clinical Trials | April 03, 2023

Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer

Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations


EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company
News | April 03, 2023

EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company

EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging


LifeSigns raises Pre-Series A
News | March 15, 2023

LifeSigns raises Pre-Series A

A funding to expand operations and provide better patient care


MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates
Clinical Trials | February 24, 2023

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months


Moderna announces advances across mRNA pipeline
News | January 10, 2023

Moderna announces advances across mRNA pipeline

Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients


BDR Pharmaceutical launches the first generic to treat Prostate cancer in India
News | January 04, 2023

BDR Pharmaceutical launches the first generic to treat Prostate cancer in India

BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.


Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine
Drug Approval | December 28, 2022

Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine

The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come


Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
Clinical Trials | November 21, 2022

Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster

Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data


Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster
Drug Approval | November 11, 2022

Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster

The European Commission will review the CHMP recommendation and is expected to make a final decision soon.